Clinical Competition Candidate

SYMBICORT AEROSPHERE

Respiratory · Asthma and COPD (ICS / LABA combination)

SYMBICORT AEROSPHERE carries product and use-code patents, low complexity (1/5), and meaningful clinical competition (5/5). The listed expiry window is approximately 47 months away. Active clinical competition may compress the generic entry window.

Back to watchlist Contact us about this drug

LOE window

47months

to latest listed patent expiry (May 28, 2030)

Expiry attractiveness: 4/5

Patent profile

Substance patent (none)

Product / formulation patent (listed)

Use-code patent (listed)

Patent count: 2

Complexity score: 1/5

Clinical competition

Score: 5/5

Active trials linked: 300

Phase 2/3 trials: 131

Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.

Drug overview

Active ingredient: BUDESONIDE; FORMOTEROL FUMARATE

Applicant (NDA holder): ASTRAZENECA PHARMACEUTICALS LP

Confidence: High

Market context

Therapeutic area: Respiratory

Indication: Asthma and COPD (ICS / LABA combination)

U.S. market size (est.)$500M+

Estimated U.S. net sales tier. Verify current figures before commercial diligence.